Ipilimumab-Induced Neutropenia in Melanoma
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia followin...
Main Authors: | Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-08-01
|
Series: | Journal of Investigative Medicine High Impact Case Reports |
Online Access: | https://doi.org/10.1177/2324709616661835 |
Similar Items
-
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
by: Wei Guoqing, et al.
Published: (2012-03-01) -
Ipilimumab cystic hypophysitis mimicking metastatic melanoma
by: John Wallace, BS, et al.
Published: (2018-06-01) -
Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011-01-01) -
Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013-08-01) -
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2016-12-01)